Morningstar

Damien Conover, CFA

Damien Conover, CFA, is director of equity research, North America, for Morningstar.

More From Damien Conover

The wide-moat drugmaker's plan to divest its consumer business will likely create only a minor level of value-creation for shareholders, at best.
Damien Conover, CFA

We think the market continues to underappreciate both Pfizer’s pipeline and recently launched drugs.
Damien Conover, CFA

Eli Lilly reported strong second-quarter results, and we don’t see the delay of rheumatoid arthritis drug baricitinib as having a material impact.
Damien Conover, CFA

Johnson & Johnson competitive position looks strong, but growth prospects don’t appear strong enough to support the current market price.
Damien Conover, CFA

The market is underappreciating the earnings growth potential of current drugs and the pipeline.
Damien Conover, CFA

Even with Humira’s expected decline, we think the company has a narrow moat.
Damien Conover, CFA

Opdivo setback aside, drugmakers Bristol, Merck, Roche and AstraZeneca are well positioned to reinforce their economic moats with transformative new immuno-oncology drugs.
Damien Conover, CFA

More About Damien Conover

Damien Conover, CFA, is director of equity research, North America, for Morningstar*.

Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.

Conover holds bachelor’s and master’s degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center